Kudo-Saito C - Search Results

1

CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer.

Oshima K, Shoji H, Boku N, Hirano H, Okita N, Takashima A, Kato K, Kudo-Saito C. Oshima K, et al. Among authors: kudo saito c. Am J Cancer Res. 2024 Mar 15;14(3):1174-1189. doi: 10.62347/NQBL9998. eCollection 2024. Am J Cancer Res. 2024. PMID: 38590413 Free PMC article.

2

IL25⁺ macrophages are a key determinant of treatment resistance of IL17RB⁺ breast cancer.

Ozaki Y, Kinowaki K, Kawabata H, Kudo-Saito C. Ozaki Y, et al. Among authors: kudo saito c. Am J Cancer Res. 2023 Oct 15;13(10):4931-4943. eCollection 2023. Am J Cancer Res. 2023. PMID: 37970362 Free PMC article.

3

Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer.

Kudo-Saito C, Boku N, Hirano H, Shoji H. Kudo-Saito C, et al. Front Immunol. 2022 Sep 23;13:1009701. doi: 10.3389/fimmu.2022.1009701. eCollection 2022. Front Immunol. 2022. PMID: 36211375 Free PMC article. Review.

4

Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma.

Ogiwara Y, Nakagawa M, Nakatani F, Uemura Y, Zhang R, Kudo-Saito C. Ogiwara Y, et al. Among authors: kudo saito c. Cancer Lett. 2022 Jul 1;537:215690. doi: 10.1016/j.canlet.2022.215690. Epub 2022 Apr 16. Cancer Lett. 2022. PMID: 35439537

5

Targeting AURKA in treatment of peritoneal tumor dissemination in gastrointestinal cancer.

Ozawa H, Imazeki H, Ogiwara Y, Kawakubo H, Fukuda K, Kitagawa Y, Kudo-Saito C. Ozawa H, et al. Among authors: kudo saito c. Transl Oncol. 2022 Feb;16:101307. doi: 10.1016/j.tranon.2021.101307. Epub 2021 Dec 10. Transl Oncol. 2022. PMID: 34902741 Free PMC article.

6

CD11b⁺DIP2A⁺LAG3⁺ cells facilitate immune dysfunction in colorectal cancer.

Kudo-Saito C, Ogiwara Y, Imazeki H, Boku N, Uemura Y, Zhang R, Kawano-Nagatsuma A, Kojima M, Ochiai A. Kudo-Saito C, et al. Am J Cancer Res. 2021 Nov 15;11(11):5428-5439. eCollection 2021. Am J Cancer Res. 2021. PMID: 34873470 Free PMC article.

7

CD11b⁺CTLA4⁺ myeloid cells are a key driver of tumor evasion in colorectal cancer.

Imazeki H, Ogiwara Y, Kawamura M, Boku N, Kudo-Saito C. Imazeki H, et al. Among authors: kudo saito c. J Immunother Cancer. 2021 Jul;9(7):e002841. doi: 10.1136/jitc-2021-002841. J Immunother Cancer. 2021. PMID: 34261702 Free PMC article.

8

Targeting Oncoimmune Drivers of Cancer Metastasis.

Kudo-Saito C, Ozaki Y, Imazeki H, Hayashi H, Masuda J, Ozawa H, Ogiwara Y. Kudo-Saito C, et al. Cancers (Basel). 2021 Feb 1;13(3):554. doi: 10.3390/cancers13030554. Cancers (Basel). 2021. PMID: 33535613 Free PMC article. Review.

9

IL33 Is a Key Driver of Treatment Resistance of Cancer.

Kudo-Saito C, Miyamoto T, Imazeki H, Shoji H, Aoki K, Boku N. Kudo-Saito C, et al. Cancer Res. 2020 May 15;80(10):1981-1990. doi: 10.1158/0008-5472.CAN-19-2235. Epub 2020 Mar 10. Cancer Res. 2020. PMID: 32156776

10

Blocking the FSTL1-DIP2A Axis Improves Anti-tumor Immunity.

Kudo-Saito C, Ishida A, Shouya Y, Teramoto K, Igarashi T, Kon R, Saito K, Awada C, Ogiwara Y, Toyoura M. Kudo-Saito C, et al. Cell Rep. 2018 Aug 14;24(7):1790-1801. doi: 10.1016/j.celrep.2018.07.043. Cell Rep. 2018. PMID: 30110636 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37 results

Search Page